Search
After switching to a new GalNAc-LNP delivery vehicle a year ago, Verve Therapeutics today announced the initial safety and efficacy data from its VERVE-102 PCSK9 base editor
Co-Founder & CEO Sek Kathiresan walks us through the data, which so far has showed a clean safety profile and an impressive ability to...
Apr 14
SF Healthcare Week: Verve's CEO on the company's two clinical programs, and more in the pipeline
Sek Kathiresan provides an update on the company's PCSK9 and ANGPTL3 clinical programs, as well for the preclinical LPA program.
Jan 12
Verve Therapeutics' CEO on today's gene editing clinical trial pause
Sek Kathiresan describes what Verve believes caused elevated liver enzymes and thrombocytopenia in a PCSK9 gene editing trial.
Apr 2, 2024
Verve's Sek Kathiresan on 2023 progress and working to bring base editing for LDL lowering to market
Sek Kathiresan discusses Verve's first-in-human data, getting an IND cleared in the United States, and the company's partnership with Lilly.
Jan 7, 2024
.png){kind=logo}
